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Abstract Recruitment of subjects is a critical aspect of prevention trials that is often overlooked by investigators.
As a consequence, accrual time is often extended, workloads may become heavy, and resource utilization is increased
in an effort to complete projects. Recruitment of healthy subjects in cancer prevention and control studies presents
unique issues that need to be considered. The barriers to recruitment include participant issues, physician variables,
features of the study design, and characteristics of the health care system in the United States. The authors provide their
experience in overcoming these difficulties. J. Cell. Biochem. Suppl. 34:80–83, 2000. r 2000 Wiley-Liss, Inc.
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The recruitment and retention of subjects are
well-recognized hurdles for clinical trials [Hun-
ninghake et al., 1987; Lovato et al., 1997], and
these difficulties demand focused efforts to over-
come. Nonetheless, the scientific foundation to
support these activities in prevention trials is
embryonic, and what is known is largely based
on treatment trials, not the healthy popula-
tions that are targets of most cancer preven-
tion.
The intent of this article is to review the
experience of the authors in recruiting and
retaining subjects in clinical trials in identify-
ing and overcoming barriers to recruitment and
retention and to address issues unique to ge-
netic and other high-risk cancer populations. A
related area is the recruitment of minority popu-
lations; this issue that has been well reviewed
elsewhere [Lovato et al., 1997; Swanson and
Ward, 1995] and is not discussed here.
BARRIERS TO RECRUITMENT
In our experience, only a small percentage of
the apparently eligible subjects will actually be
randomized. Part of the problem is the frank
ineligibility, which becomes apparent during
the recruitment process. However, even among
fully eligible subjects for prevention trials, only
a modest proportion actually take part. In re-
cent adenoma prevention trials, for example,
less than 10% of subjects initially considered
for inclusion were finally randomized. Success-
ful recruitment of subjects into cancer preven-
tion clinical trials involves a complex interac-
tion between potential subjects and study staff,
within the context of the specified study design.
Therefore, barriers to recruitment can best be
examined separately as issues arising from the
participants’ perspective, difficulties from the
point of view of physicians and other health
care providers, and problems emanating from
the trial design itself.
Participants’ Perspective
A distinguishing feature of prevention trials
is the healthy character of the target popula-
tion, in contrast to the relatively sick groups
that characterize treatment trials. Since poten-
tial participants for prevention trials are well,
and typically do not have medical problems
that demand immediate attention, they may
not feel that they will have much to gain by
entering a trial. As a consequence, it is likely
that subjects in a prevention trial are more
highly selected than those in treatment trials.
Characteristics of the participant play a major
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role in this selection for recruitment. For ex-
ample among women at high risk of breast
cancer recruited to a clinical trial, education
level was the key determinant of the impact of
other characteristics in the decision to partici-
pate [Lerman et al., 1994].
Participant attitudes are also important de-
terminants of recruitment. Participant atti-
tudes and concerns have been classified into
three general categories: feelings regarding time
and effort involved in participation, personal
and family attitudes regarding clinical trials,
and perception of benefits from trial participa-
tion [Swanson and Ward, 1995]. Of these catego-
ries, it has been our experience that time and
aggravation have the greatest influence on re-
cruitment success. Concerns regarding waiting
and travel time, time away from job and family,
child care, and parking are among some of the
issues. These may often be appropriate worries,
but can easily be exaggerated. For example, the
need to travel to an unfamiliar location may
prompt concerns regarding such issues when in
fact the perceived barriers do not really exist.
Such problems are relatively easy to overcome
by designing a system that is truly user-friendly
and emphazing to the subjects the reality. This
may include placing study sites in more conve-
nient or familiar locations for the targeted popu-
lation.
Among some potential participants, there
may be a fear of being a subject of investigation,
in particular a hesitancy to submit to random-
ization. This concern may be more common
among minority individuals, those who are less
well educated, and those of lower socioeconomic
class. Recruitment may also be difficult if evi-
dence of the study’s benefit (to the individual or
to society) is unclear. This is an especially impor-
tant oversight, as many participants enroll in
prevention trials for altruistic reasons. To avoid
such problems, the authors have clarified the
concerns of possible participants through com-
munity advisory boards, in-depth interviews
with likely study participants, and focus groups.
Physicians and Other Health Care Providers
The cooperation and participation of physi-
cians and other health care providers are often
essential to the success of recruitment to clini-
cal trials; it will clearly be an important issue in
multicentered studies. Physicians often serve
as gatekeepers of access to trials; as such, they
can either facilitate or prevent access to the
trial. Indeed, the most common reason that a
cancer patient is not enrolled in a trial is that
the patient’s physician made a decision not to
enter that patient in the trial [Foley and Moer-
tel, 1991].
Several factors contribute to whether physi-
cians will be a barriers or facilitators. Trials
requiring significant amount of time and effort
for physicians or the office staff will not be
welcomed. Studies interfering with the doctor/
patient relationship are also going to be re-
jected. This may be an ever-increasing barrier
as patients are viewed as a commodity to physi-
cians. Physicians may fear losing patients to
competing clinicians if they are referred to par-
ticipate in a trial. Finally, and most impor-
tantly, there is a conflict between physicians
role as care giver and scientist. As caregivers,
physicians place the interests of the individual
first. As scientists, the benefit to humanity is
placed first, including well-designed trials that
use informed consent and randomization. Both
issues are a dramatic paradigm shift from the
daily activities of clinical practice.
The authors have used several strategies to
overcome physician-related barriers. First, to
the maximum extent possible, the trial can not
add extra responsibilities to the workload of the
physician or their office staff. This means that
studies should have staff and resources to ac-
cess the subjects, deliver the study protocol,
and collect the data. Second, the single most
important persons critical to success of any
study in a physician’s office are the front office
staff such as the receptionist, telephone opera-
tor, and medical records staff. Thus, investiga-
tors should follow the lead of the drug company
representatives and court these staff members
with incentives and rewards—or at the very
least treat them with a great deal of respect.
Third, community-based physicians will greatly
appreciate public acknowledgment and reward
for their participation in studies. This goal can
be accomplished with official appearing plaques
for the office, local newspaper stories, or promo-
tion of the physician as a local expert or re-
source at hospital staff meetings.
The health care system in the United States
is also a factor that relates to the ability of
physicians and other health care providers to
recruit subjects. The health care system in the
United States is not actually a system; rather,
it can best be described as a chaotic, loosely
connected network based primarily on employ-
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ment status. This makes it quite difficult to
identify and access potential participants
through a single, central source. One strategy
to overcome this barrier is to use local organiza-
tion that can serve as a single source of informa-
tion. For example, managed care or health main-
tenance organizations can be a useful
infrastructure to use to access subjects for can-
cer prevention and control trials [Hudmon et
al., 1997].
Trial Design Barriers
Trial designs and requirements are often very
complex, and the complexity can be a signifi-
cant barrier to recruitment. The intervention
itself may be perceived as distasteful, such as
diet changes or weight loss. The protocol may
be invasive, such as flexible sigmoidoscopy with
colorectal biopsies or even multiple blood draws.
The intervention may be perceived as having
too many undesirable side effects. Healthy sub-
jects are not willing to take as much risk as are
those who have illnesses. Thus, it is important
that trials keep invasive procedures to a mini-
mum, minimize the risk of adverse events, and
maximize the possibility and evidence of ben-
efit.
Perhaps the fundamental aspect of trial de-
sign that hampers completion of recruitment is
simply the large sample sizes required. This
typically forces a multicentered design that will
magnify the administrative complexity of the
study considerably. The fact that large num-
bers of subjects are required will put a pre-
mium on efficient and timely recruitment. In
the Polyp Prevention Study Group, several facts
about recruitment have become clear. First,
clinicians regularly tend to overestimate the
volume of suitable patients in their practices.
Often, as clinicians consider their own practice,
the eligibility criteria for of the trial being con-
sidered are discounted. For example, a clinician
may perceive that their practice volume of colo-
noscopies is high. The perception of a large
volume of eligible participants is false, since a
substantial proportion of the practice consists
of colon cancer follow-up, not colonic polyps. It
is the volume of eligible subjects that is impor-
tant. This has proven to be true of studies
recruiting women undergoing colposcopy.
Second, once the planning is completed and
recruitment actually begins, then it is impor-
tant to introduce an active recruitment pro-
gram. Relying on clinicians to remember to
refer patients, or expecting advertisements
and/or flyers to provide a brisk volume of pa-
tients, is unrealistic. Use of some sort of sam-
pling frame is much more effective, such as a
list of potentially eligible subjects who can be
systematically approached to investigate par-
ticipation. Other useful strategies are using
recruitment coordinators, regular meetings
(weekly or monthly) focused on recruitment,
involvement of the principal investigator in re-
cruiting (especially with interaction with other
physicians), and setting goals. Finally, investi-
gators should never fail to remind colleagues
and reintroduce the enthusiasm for studies too
often.
Retention of Subjects
Once the struggle to achieve a recruitment
target is reached, there may be a natural ten-
dency to breathe a sigh of relief and relax.
Unfortunately, retention of randomized sub-
jects, though typically less aggravating than
recruitment, requires considerable sustained
effort.
A run-period before randomization is one
early strategy that can be employed to main-
tain the compliance of subjects in the trial. By
identifying subjects who are likely to drop out,
a run-in can provide some measure of protec-
tion. In the trials conducted by the Polyp Pre-
vention Study Group, 15–20% of subjects who
entered the run-in periods of the trials con-
ducted have been deemed unsuitable for ran-
domization. Presumably these subjects would
have dropped out if they had been randomized.
Nonetheless, even subjects who successfully
complete the run-in period may present difficul-
ties regarding retention. In the relatively long
trials of conducted by the Polyp Prevention
Study Group (3–5 years), many of the dropouts
have occurred because of comorbidity, and not
directly because of the burdens of the study
itself. This pattern is particularly difficult to
combat—since no single characteristic of the
trial has led to the dropout, there is not much
specific that the study can do to prevent it,
other than making continued participation as
painless as possible. The approach has been to
have study staff tailor a supportive approach to
the individual subjects. For many subjects, this
involves the establishment of a personal rap-
port entailing frequent contact regarding frus-
trations. This rapport is best established if study
participants have continuity with the same re-
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search staff person throughout the duration of
the study. Simple jesters such as birthdays and
Holiday cards (used in the Polyp Prevention
Study), inquiries about family members, listen-
ing to complaints about life stresses unrelated
to the study, and assisting in solving unrelated
health issues help to create committed study
participants. From the point of view of both the
clinicians and the study subjects, retention will
be maximized if follow-up investigations are
incorporated into routine care: following ex-
pected ‘‘routine’’ timing, and involving as little
deviation from routine as possible.
UNIQUE ISSUES TO GENETIC AND
HIGH-RISK IDENTIFICATION
One unique aspect of some studies in cancer
prevention and control is the identification of
study subjects with genetic abnormalities. Dif-
ficult issues may arise both for the individual
participant as well as for family members. Sub-
jects participating in studies involving genetic
testing have to consider risk such as discrimina-
tion and loss of insurability or employability if
they are identified has carrying the genetic
abnormality. In addition, family members of
the study participants may face dealing with
genetic information as well as discrimination
similar to that the subject faces, but without
informed consent. Not only are adults within
the family affected, but children as well. These
issues are only just beginning to be encoun-
tered among investigators and institutional re-
view boards. There are currently no guidelines
nor is clear that all of the risk are known.
FUTURE PROSPECTS
Investigators need to place more effort on
recruitment and retention of subjects in cancer
prevention and control trials. This requires more
understanding of the barriers and knowledge
regarding the success of strategies to overcome
these barriers. The published data on various
strategies to improve recruitment and reten-
tion are very limited. More investigators are
needed in this area. Investigators focusing more
on the successes of their strategies and adding
the experience to the published data would be
extremely useful. The unique issues associate
with participation in trials involving genetic
testing needs more exploration.
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